The Company was incorporated as Bajaj Healthcare Pvt. Ltd. on July 15, 1993 under the Companies Act, 1956, with the Registrar of Companies, Mumbai bearing Registration Number - 072892. The status of the Company was changed to a public limited company and the name of the Company was changed to Bajaj Healthcare Ltd. by a special resolution passed on March 15, 2005. A fresh certificate of incorporation consequent to the change of name was granted to the Company on March 31, 2005, by the Registrar of Companies, Mumbai. The Company's Corporate Identity Number is U99999MH1993PLC072892. the Company, Bajaj Healthcare Limited, is a pharmaceutical company with manufacturing and marketing capabilities in Active Pharmaceutical Ingredients (APIs), Intermediates and Finished Dosage Formulations (FDFs) with focus on Vitamins, Amino Acids, Anti-Convulsants and Finished Dosage Forms (FDFs) catering to various therapeutic segments. the Company began its operations in the year 1993 with an API manufacturing unit in Tarapur, near Mumbai. Over the years we have expanded the scale and scope of operations and currently we operate five (5) manufacturing units for manufacture of APIs, Intermediates and Formulations. As part of this expansion, in the year 2006, we acquired a 46,000 sq. mtrs. plant in Savli, Vadodara for setting up one of the biggest API and Intermediate manufacturing units. In the year 2008, with a view to enter into manufacturing of FDFs, we acquired a 3,000 sq. mtrs. Formulations plant at Manjusar, Vadodara and we have converted it into a state-of-the-art WHO-GMP compliant facility. Keeping in momentum of the expansion, in the year 2013, we set-up yet another API and Intermediate manufacturing unit at Panoli, Ankleshwar. In the last fiscal, i.e. in F. Y. 14-15, with the growing demand for APIs, we decided to have a separate unit for Intermediate products so that the Savli and Panoli Units could concentrate on manufacture of APIs. Accordingly, in November 2014 we acquired and set-up an Intermediate Unit in Tarapur MIDC, near Mumbai. the Company's present product portfolio consists of various APIs in the therapeutic categories of Neutraceutical (Amino Acids), Vitamins, Anti-Convulsants, Bactericidal & Bacteriostatic, Diuretic & Vasodilator, Mineral& Nutritional supplements, Bronchodilater / Anti-asthmatic and Nootropics. the Formulations unit manufactures tablets, capsules and sachets for the own brands as well as under Loan License (job work) for other pharmaceutical companies. Currently, we manufacture formulations for GlaxoSmithKline Pharmaceuticals Limited (GSK) and USV Limited (USV) on a Loan License basis. The formulations manufactured for the own brands are manufactured and marketed under a separate division of Bajaj Medicare and we also have marketing tie-up with TTK Healthcare Limited. The FDFs manufactured by us cover various therapeutic segments like Antibiotics, Anti-Arrhythmia, Anti-Convulsants, Anti-Diabetes, Anti-Platelets, NSAIDs, Vitamins & its Derivatives, Anti-Hypertensive, Anti-Bacterial, Anti-Malarial, Cholinesterase Inhibitors, etc. With the combined production of the API facilities and that of the Formulation unit, the Company's product portfolio consists of APIs and FDFs which shall be marketed in domestic and international markets as branded generics. Presently we are supplying the APIs and FDFs both domestically and exporting to various countries in regions like, Europe, USA, Australia, Africa, South America, etc. With the long standing operations and quality products, we have built a strong relationship with the customers for both APIs and FDFs. Some of the major clients include nationally and internationally pharmaceutical companies like Glaxo Smithkline Consumer Healthcare Ltd., Ava Inc., Abbott Healthcare Pvt.Ltd, Piramal Enterprises Ltd., Pfizer Ltd., Colgate Palmolive India Ltd., Lupin Ltd. and Intas Pharmaceuticals to name a few. We have an in-house R&D facility at the Tarapur, Savli and Manjusar manufacturing units and a dedicated QC / QA & microbiology laboratory in all the Units to support technology transfer for new products and on-site process improvement. As on date of this Draft Prospectus, we dedicated teams actively involved in R&D and QC / QA Lab activities. the R&D capabilities enable us to support the growth strategy by developing new products and processes which enhance the product range. The focus of the R&D has been to strive for continuous process improvements and achieving manufacturing cost efficiencies for existing as well as new APIs, Intermediates and FDFs. The QA / QA and microbiology laboratories ensure the quality of raw material dispensed in the production process and also the finished goods delivered to the customers. This helps in improving the procurement process thus reducing wastages, returns and other related costs. MAJOR EVENTS : 1993-94 -Incorporated under Companies Act, 1956 as Bajaj Healthcare Private Limited by setting up plant at Tarapur 1996-97 -1st Export Sale 2004-2005 -Changed the status of the Company from Private to Public i.e. to Bajaj Healthcare Limited. 2005-2006 -Purchase and Set-up a new facility at Salvi, Vadodara -Purchase addition Plot N- 128 at Tarapur -Set up Corporate Office in Masjid Bunder (The same was acquired in FY 2003- 2004) 2006-2007 -Issued 20,00,000, Non- Cumulative Preference Shares of 10/- each -Major Term loan of 863.00 lakhs was sanction and the total indebtedness reached to 2,265 lakhs 2007-2008 -Purchase and Set-up a new facility at Manjusar, Vadodara -Increase in Capacity of the major products like; 100% Vitamin C and its derivatives and 50% in Choline Bitartrate, etc. 2009-2010 -Launched own brands under Manjusar/ Medicare 2013-2014 -Purchase and Set-up a new facility at Panoli, Ankleshwar -1st GVK Agreement -1st USV Agreement 2014-2015 -Purchase and Set-up a Second facility at Tarapur, Maharashtra 2016 -Bajaj Healthcare has Listing of equity shares of Bajaj Healthcare Ltd -Bajaj Healthcare Ltd has informed that the Company's registered office has been shifted from N-216, Tarapur, Boisar, Dist. Palghar to 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Industrial Estate, Thane (west), Thane-400 604 w.e.f. August 31, 2016. 2019 -The Company has issued Bonus Shares in the Ratio of 1:1. 2021 -The Company has splits its face value from Rs. 10/- to Rs. 5/-. 2022 -Company Inaugurated a new production line for Processing of Opium at Savli, Gujarat,